title: Nanotrastuzumab in combination with radioimmunotherapy: Can it be a viable treatment option for patients with HER2-positive breast cancer with brain metastasis?
abstract: Brain metastasis of primary breast cancer (BCBM) has been rising during the last couple of decades. Approximately 25% of the patients with BCBM have a hormone receptor-negative, HER2-positive disease. Given the short life expectancy in patients with BCBM, researchers have tried many new approaches, including cesium-131(131Cs) brachytherapy, radretumab radioimmunotherapy and nanoparticles. Novel biological drug delivery techniques have successfully delivered nanobioconjugates across the blood-brain barrier (BBB). However, nanobioconjugates have significant toxicities and other drawbacks that prevent therapeutic concentrations of the active drug from being delivered to the brain lesions. Radretumab radioimmunotherapy combined with nanotrastruzumab can theoretically overcome this challenge. Radiotherapy can increase the BBB permeability, which can promote the transport and effect of nanotrastuzumab, reduce radretumab radioimmunotherapy dose and target patients with HER2-positive BCBM lesions more specifically. In this article, we propose that nanotrastuzumab in combination with radioimmunotherapy could be a viable treatment option for patients with HER2-positive breast cancer with brain metastasis.
authors.affiliation: Breast Surgery Department, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College and Hospital, Shanxi Provincial People's Hospital, China.
authors.forename: Xuefei
authors.initials: X
authors.lastname: Wang
authors.affiliation: Breast Surgery Department, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College and Hospital, Shanxi Provincial People's Hospital, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Sun
authors.affiliation: Breast Surgery Department, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College and Hospital, Shanxi Provincial People's Hospital, China.
authors.forename: Songjie
authors.initials: S
authors.lastname: Shen
authors.affiliation: Breast Surgery Department, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College and Hospital, Shanxi Provincial People's Hospital, China.
authors.forename: Yali
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Breast Surgery Department, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College and Hospital, Shanxi Provincial People's Hospital, China.
authors.forename: Likun
authors.initials: L
authors.lastname: Huang
mesh_terms: D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy*; D002586:Cesium / Q000737:chemistry; D006801:Humans; D008962:Models, Theoretical; D009362:Neoplasm Metastasis; D009360:Neoplastic Cells, Circulating; D010539:Permeability; D016499:Radioimmunotherapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D002586:Cesium; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human